Picture EBD Group World of Partnering Opportunities 650x100px
Document › Details

Abzena plc. (8/16/18). "Press Release: Update on Partial Monetisation of Abzena Inside Portfolio". Cambridge.

Organisations Organisation Abzena plc (AIM: ABZA)
  Today Abzena Ltd. (since 2018)
  Group Abzena (Group)
  Organisation 2 Welsh, Carson, Anderson and Stowe XII, L.P. (WCAS XII)
  Group Welsh, Carson, Anderson & Stowe (WCAS)
Products Product drug development services
  Product 2 private equity
Index term Index term Abzena–Welsh Carson Anderson & Stowe: investment, 201808– recommended cash offer 16p/share valueing Abzena at £34.4m by WCAS XII-Astra LP
Persons Person Burt, John (Abzena 201405– CEO before Antitope + PolyTherics + Thiakis)
  Person 2 Toyne-Sewell, Melanie (Instinctif Partners 201509)

Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Company’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, confirms that following the announcement today of a recommended cash offer for the Company, it has terminated discussions to sell an interest in its entitlements to future royalties which may arise from certain ABZENA Inside products.

This announcement is released by Abzena plc and contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 (“MAR”), encompassing information relating to the Group’s fundraising activities, and is disclosed in accordance with the Company’s obligations under Article 17 of MAR.

For the purposes of MAR and Article 2 of Commission Implementing Regulation (EU) 2016/1055, this announcement is being made on behalf of the Company by John Burt, Chief Executive Officer.


Abzena plc
John Burt, Chief Executive Officer
+44 1223 903498

Numis Securities (Nominated Adviser and Broker)
Paul Gillam (Corporate Finance)
James Black (Corporate Broking)
+44 20 7260 1000

N+1 Singer (Joint Broker)
Aubrey Powell / Liz Yong
+44 20 7496 3000

Instinctif Partners
Melanie Toyne Sewell / Rozi Morris / Alex Shaw
+44 20 7457 2020

Notes to Editors

About Abzena

Abzena (AIM: ABZA) provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products.

The term ‘ABZENA Inside‘ is used by Abzena to describe products that have been created using its proprietary technologies and are being developed by its partners, and include Composite Human Antibodies™ and ThioBridge™ Antibody Drug Conjugates (ADCs). Abzena has the potential to earn future licence fees, milestone payments and/or royalties on ABZENA Inside products.

Abzena offers the following services and technologies across its principal sites in Cambridge (UK), San Diego, California (USA) and Bristol, Pennsylvania (USA):

> Biology research studies, including immunogenicity assessment of candidate biopharmaceutical products and bioassay development;
> Protein engineering to create humanized antibodies and deimmunised therapeutic proteins;
> Cell line development for the manufacture of recombinant proteins and antibodies;
> Contract process development and GMP manufacture of biopharmaceuticals, including monoclonal antibodies and recombinant proteins for preclinical and clinical studies;
> Contract synthetic chemistry and bioconjugation research services, focused on antibody-drug conjugates (ADCs);
> Proprietary site-specific conjugation technologies and novel payloads for ADC development;
> GMP manufacturing of ADC linkers, payloads & combined linker-payloads; and
> GMP analytical services for biopharmaceutical manufacturing projects.

For more information, please see

Record changed: 2023-06-05


Picture Berlin Partner Voices Robinson Data for Precision Medicine 650x200px

More documents for Abzena (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x300px

» top